Enhanced cellular consumption of cancer cells could revolutionize how engineered immune therapies attack tumors. Current CAR-T therapies face limitations in solid tumors, creating urgent demand for more effective approaches that can penetrate and destroy established cancer masses. A critical breakthrough demonstrates how manipulating Rac protein activity transforms the tumor-eating capacity of engineered macrophages. When Rac becomes hyperactive in chimeric antigen receptor-macrophages (CAR-M), these immune cells shift from partial to complete consumption of target cancer cells through trogocytosis—a process where one cell literally eats pieces of another. The hyperactive Rac variant converts what would normally be survivable cellular nibbling into lethal tumor destruction, dramatically enhancing therapeutic efficacy in living systems. This finding addresses a fundamental challenge in cancer immunotherapy: how to make engineered immune cells more aggressive against established tumors. Unlike CAR-T cells that primarily work through cytotoxic signaling, CAR-M therapy relies on direct cellular consumption, potentially offering advantages in solid tumor penetration and persistence. The Rac enhancement strategy represents a significant advance in cellular engineering for cancer treatment. However, the approach requires careful evaluation of off-target effects, as hyperactive Rac could potentially affect normal tissue macrophages. The research also raises questions about optimal dosing and delivery methods for clinical translation. While promising, this represents early-stage research requiring extensive safety testing before human trials. The work nonetheless opens new avenues for engineering more potent cellular immunotherapies.